EUVIMEDEUVIMED entdecken
Open Access

Evaluation of HER2 immunohistochemistry expression in non-standard solid tumors from a Single-Institution Prospective Cohort

Saurav Verma iD, Amanda Chapman, Lee-Anne Pickard, Danielle Porplycia, Haley McConkey, Patricia Jarosz, James Sinfield, Carolyn Lauzon-Young, Matthew J Cecchini, Christopher Howlett, Natalie Grindrod, Bekim Sadikovic und 2 weitere

Exploration of Targeted Anti-tumor Therapy · 22.08.2024 · 5 (5) · 1100-1109

DOI: 10.37349/etat.2024.00265 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Exploration of Targeted Anti-tumor Therapy, online erschienen am 22.08.2024. Verfasst von Saurav Verma und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Oncology, Schulich School of Medicine & Dentistry, Western University, London, ON N6A 5C1, Canada. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Human epidermal growth factor receptor-2 (HER2) is a well-established prognostic and predictive biomarker. It is an FDA-approved therapeutic target for HER2 positive breast, gastroesophageal, and more recently, lung and colon cancers. It is an emerging biomarker in biliary tract, bladder, cervical, endometrial, ovarian, and pancreatic cancers. The emergence of new indications warrants further characterization of HER2 expression in diverse cancer populations. This study investigated HER2 expression in solid tumour samples and the feasibility of obtaining these results.

Methods

Prospective consent was obtained at a Canadian tertiary academic cancer center from adult oncology patients who were referred for molecular genetic testing of malignant tissue samples. Standard HER2-targeted malignancies were considered breast and gastroesophageal, and were excluded from this study. Between July 2020 and November 2023, 499 samples of solid tumors underwent immunohistochemistry (IHC) HER2 staining. A median turnaround time (TAT) of 14 days would be considered feasible for clinical decision making.

Results

The mean age (± SD) of participants was 67 ± 12.5 years, with 270 (54%) male and 229 (46%) female. HER2 protein expression was measured in 42 unique cancer types. IHC levels of 0, 1+, 2+, and 3+ were reported and were 43%, 12%, 35%, and 10% of all analyzable samples respectively (tissue inadequate in 3% of samples). The median TAT for HER2 expression results from time of request to result in release was 18 (interquartile range, 11 to 30) days.

Conclusions

HER2 protein expression varies widely between different cancer types. TAT for HER2 IHC results was a median of 18 days, which is close to our feasibility cut-off.

Schlagwörter

Stichwörter der Autor:innen

HER2IHCbiomarkersolid tumors

Autor:innen und Institutionen

  • Division of Medical Oncology, Department of Oncology, Schulich School of Medicine & Dentistry, Western University, London, ON N6A 5C1, Canada.
  • Verspeeten Family Cancer Centre, London Health Sciences Centre, London, ON N6A 5W9, Canada.
  • Department of Medicine, Schulich School of Medicine & Dentistry, Western University, London, ON N6A 5C1, Canada.
  • Department of Pathology and Laboratory Medicine, London Health Sciences Centre, London, ON N6A 5W9, Canada.
  • Department of Pathology and Laboratory Medicine, Schulich School of Medicine & Dentistry, Western University, London, ON N6A 5C1, Canada.

ORCID-Profile: Saurav Verma, Stephen A Welch, Daniel Breadner

Zitieren

APA

Verma, S., Chapman, A., Pickard, L. A., Porplycia, D., McConkey, H., Jarosz, P., Sinfield, J., Lauzon-Young, C., Cecchini, M. J., Howlett, C., Grindrod, N., Sadikovic, B., Welch, S. A., & Breadner, D. (2024). Evaluation of HER2 immunohistochemistry expression in non-standard solid tumors from a Single-Institution Prospective Cohort. Exploration of Targeted Anti-tumor Therapy, 5(5), 1100-1109. https://doi.org/10.37349/etat.2024.00265

Vancouver

Verma S, Chapman A, Pickard LA, Porplycia D, McConkey H, Jarosz P, et al. Evaluation of HER2 immunohistochemistry expression in non-standard solid tumors from a Single-Institution Prospective Cohort. Exploration of Targeted Anti-tumor Therapy. 2024;5(5):1100-1109. doi:10.37349/etat.2024.00265

BibTeX
@article{Verma2024,
  author = {Verma, Saurav and Chapman, Amanda and Pickard, Lee-Anne and Porplycia, Danielle and McConkey, Haley and Jarosz, Patricia and Sinfield, James and Lauzon-Young, Carolyn and Cecchini, Matthew J and Howlett, Christopher and Grindrod, Natalie and Sadikovic, Bekim and Welch, Stephen A and Breadner, Daniel},
  title = {Evaluation of HER2 immunohistochemistry expression in non-standard solid tumors from a Single-Institution Prospective Cohort},
  journal = {Exploration of Targeted Anti-tumor Therapy},
  year = {2024},
  volume = {5},
  number = {5},
  pages = {1100--1109},
  doi = {10.37349/etat.2024.00265}
}
Kostenlos starten →